Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Results from the NIVOREN GETUG-AFU 26 study.

被引：9

作者：

Albiges, Laurence

Negrier, Sylvie

Dalban, Cecile

Gravis, Gwenaelle

Chevreau, Christine

Oudard, Stephane

Laguerre, Brigitte

Barthelemy, Philippe

Borchiellini, Delphine

Gross-Goupil, Marine

Geoffrois, Lionnel

Brihoum, Meryem

Escudier, Bernard

机构：

[1] Univ Paris Sud, Gustave Roussy Inst Oncol, Villejuif, France

[2] Ctr Leon Berard, Lyon, France

[3] Inst Paoli Calmettes, Marseille, France

[4] IUCT Oncopole Inst Claudius Regaud, Toulouse, France

[5] AP HP, Hop Europeen Georges Pompidou, Paris, France

[6] Ctr Eugene Marquis, Rennes, France

[7] Hopitaux Univ Strasbourg, Strasbourg, France

[8] Ctr Antoine Lacassagne, Nice, France

[9] Ctr Hosp Univ St Andre, Bordeaux, France

[10] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France

[11] UNICANCER, Paris, France

[12] Gustave Roussy Canc Campus, Villejuif, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期

关键词：

D O I：

10.1200/JCO.2018.36.6_suppl.577

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

577

引用

页数：1

共 50 条

[31] Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP).
De Giorgi, Ugo
Scagliarini, Sarah
Basso, Umberto
Galli, Luca
Mosillo, Claudia
Caserta, Claudia
Rossetti, Sabrina
Guida, Annalisa
Bearz, Alessandra
Buti, Sebastiano
Lo Re, Giovanni
Valcamonico, Francesca
Hamzaj, Alketa
Cognetti, Francesco
Rastelli, Francesca
Fornarini, Giuseppe
Porta, Camillo
Del Bene, Gabriella
Turci, Daniele
Procopio, Giuseppe
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[32] PHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC)
Hammers, H.
Plimack, E. R.
Infante, J. R.
Ernstoff, M.
Rini, B. I.
McDermott, D. F.
Razak, A.
Pal, S. K.
Voss, M.
Sharma, P.
Kollmannsberger, C. K.
Heng, D.
Shen, Y.
Kurland, J.
Spratlin, J.
Gagnier, P.
Amin, A.
ANNALS OF ONCOLOGY, 2014, 25
[33] Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).
Hammers, Hans J.
Plimack, Elizabeth R.
Infante, Jeffrey R.
Ernstoff, Marc S.
Rini, Brian I.
McDermott, David F.
Razak, Albiruni R. A.
Pal, Sumanta Kumar
Voss, Martin Henner
Sharma, Padmanee
Kollmannsberger, Christian K.
Heng, Daniel Yick Chin
Spratlin, Jennifer L.
Shen, Yun
Kurland, John F.
Gagnier, Paul
Amin, Asim
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[34] Association of microbiome to nivolumab response in metastatic renal cell carcinoma (mRCC)
Maia, Manuel
Poroyko, Valeriy
Won, Hae
Bergerot, Paulo
Almeida, Lorena
Dizman, Nazli
Hsu, JoAnn
Jones, Jeremy
Salgia, Ravi
Pal, Sumanta
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[35] Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study.
Sharma, Padmanee
Callahan, Margaret K.
Bono, Petri
Kim, Joseph W.
Spiliopoulou, Pavlina
Calvo, Emiliano
Pillai, Rathi Narayana
Ott, Patrick Alexander
De Braud, Filippo G.
Morse, Michael
Le, Dung T.
Taylor, Matthew H.
Bendell, Johanna C.
Jager, Dirk
Chism, David D.
Antonia, Scott Joseph
Aanur, Nivedita
Yang, Lingfeng
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[36] Updated Safety and Efficacy Results for Sunitinib From a Global, Expanded-Access Trial in Metastatic Renal Cell Carcinoma (mRCC)
Gore, M.
Porta, C.
Bracarda, S.
Crino, L.
Hawkins, R.
Bjarnason, G.
Oudard, S.
Lee, S. H.
Kim, T. M.
Szczylik, C.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S515 - S515
[37] Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
De Giorgi, Ugo
Carteni, Giacomo
Giannarelli, Diana
Basso, Umberto
Galli, Luca
Cortesi, Enrico
Caserta, Claudia
Pignata, Sandro
Sabbatini, Roberto
Bearz, Alessandra
Buti, Sebastiano
Lo Re, Giovanni
Berruti, Alfredo
Bracarda, Sergio
Cognetti, Francesco
Rastelli, Francesca
Fornarini, Giuseppe
Porta, Camillo
Turci, Daniele
Sternberg, Cora N.
Procopio, Giuseppe
Falcone, A.
Roila, F.
Cascinu, S.
Tirelli, U.
Giustini, L.
Sobrero, A.
Cappuzzo, F.
Tortora, G.
Tassinari, D.
Passalacqua, R.
Pazzola, A.
Surico, G.
Maio, M.
Benedetti, G.
Barone, C.
Adamo, V.
Ricevuto, E.
De Censi, A.
Spada, M.
Tonini, G.
Pinto, C.
Ciuffreda, L.
Ruggeri, E. M.
Bengala, C.
Scotti, V.
Fagnani, D.
Bonetti, A.
Mitterer, M.
Castiglione, F.
BJU INTERNATIONAL, 2019, 123 (01) : 98 - 105
[38] Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hammers, Hans J.
Plimack, Elizabeth R.
Infante, Jeffrey R.
Rini, Brian I.
McDermott, David F.
Lewis, Lionel D.
Voss, Martin H.
Sharma, Padmanee
Pal, Sumanta K.
Razak, Albiruni R. Abdul
Kollmannsberger, Christian
Heng, Daniel Y. C.
Spratlin, Jennifer
McHenry, M. Brent
Amin, Asim
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (34) : 3851 - +
[39] Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)
Hammers, Hans J.
Plimack, Elizabeth R.
Infante, Jeffrey R.
Rini, Brian I.
McDermott, David F.
Ernstoff, Marc
Voss, Martin Henner
Sharma, Padmanee
Pal, Sumanta Kumar
Razak, Albiruni R. A.
Kollmannsberger, Christian K.
Heng, Daniel Yick Chin
Spratlin, Jennifer L.
Shen, Yun
Gagnier, Paul
Amin, Asim
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[40] Expanded cohort results from CheckMate 016: a Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC)
Hammers, Hans J.
Plimack, Elizabeth R.
Lnfante, Jeffrey R.
Rini, Brian I.
Mcdermott, David F.
Ernstoff, Marc S.
Voss, Martin H.
Sharma, Padmanee
Pal, Sumanta K.
Razak, Albiruni
Kollmannsberger, Christian
Heng, Daniel Y. C.
Spratlin, Jennifer
Shen, Yun
Gagnier, Paul
Amin, Asim
BJU INTERNATIONAL, 2015, 116 : 11 - 11

← 1 2 3 4 5 →